---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-025338"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:53:55.880715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones

## Summary
- Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.
- Servier will lead global development and commercialization of BDTX-4933 in RAF/RAS-mutant solid tumors, including NSCLC.
- BDTX-4933 is a Phase 1 small molecule designed to target RAS mutations and RAF alterations with best-in-class potential.
- Black Diamond continues to advance its MasterKey platform; deal provides non-dilutive capital to support pipeline.

## SEC filing metadata
- accession: 0001104659-25-025338
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465925025338/0001104659-25-025338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465925025338/tm259476d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-025338
- JSON: https://secwatch.observer/filing/0001104659-25-025338.json
- Plain text: https://secwatch.observer/filing/0001104659-25-025338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.